Retrospective Study
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Dec 26, 2020; 8(24): 6264-6273
Published online Dec 26, 2020. doi: 10.12998/wjcc.v8.i24.6264
Risk factors for de novo hepatitis B during solid cancer treatment
Rie Sugimoto, Masayuki Furukawa, Takeshi Senju, Yoshihusa Aratake, Mototsugu Shimokawa, Yuki Tanaka, Hiroki Inada, Tatsuya Noguchi, Lingaku Lee, Masami Miki, Yuji Maruyama, Risa Hashimoto, Terumasa Hisano
Rie Sugimoto, Masayuki Furukawa, Takeshi Senju, Yoshihusa Aratake, Yuki Tanaka, Hiroki Inada, Tatsuya Noguchi, Lingaku Lee, Masami Miki, Yuji Maruyama, Risa Hashimoto, Terumasa Hisano, Department of Hepato-Biliary-Pancreatology, National Hospital Organization Kyushu Cancer Center, Fukuoka City 811-1395, Fukuoka Prefecture, Japan
Mototsugu Shimokawa, National Hospital Organization Kyushu Cancer Center, Clinical Research Institute, Fukuoka City 811-1395, Fukuoka Prefecture, Japan
Mototsugu Shimokawa, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Ube City 755-8505, Yamaguchi Prefecture, Japan
Author contributions: Sugimoto R designed the study, collected and analyzed the data, and drafted the first manuscript; Furukawa M prepared and reviewed the manuscript; Senju T and Aratake Y collected and analyzed the data; Shimokawa M analyzed and reviewed the data; Tanaka Y, Inada H and Noguchi T collected the data; Lee L and Miki M participated in the acquisition and interpretation of the data; Maruyama Y prepared and reviewed the manuscript; Hashimoto R and Hisano T analyzed the data.
Supported by Eisai Corporation, No. HHCS20181030011.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of the National Hospital Organization Kyushu Cancer Center (Approval No.2017-16).
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to participate in clinical research by written consent. For full disclosure, the details of the study are published on the home page of National Hospital Organization Kyushu Cancer Center and patients are asked to inform us if they disagree with the use of the clinical data.
Conflict-of-interest statement: This work was partly supported by funding from Eisai (Grant No. HHCS20181030011) (Tokyo, Japan); however, that did not result in potential conflicts for this study because it was designed and performed independently of this funding agency.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at sugirie5@yahoo.co.jp. Participants gave informed consent for data sharing.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Rie Sugimoto, MD, PhD, Chief Doctor, Department of Hepato-Biliary-Pancreatology, National Hospital Organization Kyushu Cancer Center, 3-1-1 Notame Minami-ku, Fukuoka City 811-1395, Fukuoka Prefecture, Japan. sugirie5@yahoo.co.jp
Received: August 31, 2020
Peer-review started: August 31, 2020
First decision: September 30, 2020
Revised: October 13, 2020
Accepted: November 2, 2020
Article in press: November 2, 2020
Published online: December 26, 2020
Processing time: 110 Days and 4.6 Hours
ARTICLE HIGHLIGHTS
Research background

Hepatitis B virus (HBV) reactivation occurs in both hepatitis B surface antigen-negative and hepatitis B core antibody (HBcAb)-positive patients during chemotherapy for malignant solid tumors. The risk factors for such reactivation are unclear.

Research motivation

Identification of risk factors for HBV reactivation could result in more careful follow-up of patients with HBV DNA who are at high risk, whereas those at low risk could be followed up at less frequent intervals or stop follow-up altogether.

Research objectives

We aimed to identify the factors that contribute to hepatitis B reactivation during treatment of solid tumors. By analyzing many factors in a large cohort, we hoped to identify the most important ones and thus facilitate elucidation of the mechanism of hepatitis B reactivation.

Research methods

This was a retrospective cohort study of patients with solid tumors attending a single cancer center. Of particular note are the large cohort (1040 cases) and long follow-up period (10-years).

Research results

High HBcAb titer and cancers in organs involved in digestion and absorption were identified as independent factors for HBV reactivation.

Research conclusions

The site of the primary cancer was found to be a risk factor for hepatitis B reactivation during solid cancer treatment.

Research perspectives

Future prospective studies with a large cohort research are required to further investigate the relationship between sites of primary cancers and hepatitis B reactivation.